Latest News
vivoVerse at SOT 2023 in Nashville
The 2023 Society of Toxicology (SOT) Annual Meeting is coming up this month, and we will be attending! The SOT Annual Meeting is one of the largest gatherings of toxicologists from around the world...
vivoVerse awarded SBIR Phase II grant from NIMH
vivoVerse (formerly operating as Newormics) is excited to announce it has been awarded a $2.25M Phase II SBIR grant from the National Institutes of Health/National Institute of Mental Health (NIMH) for the continued development of the company’s in vivo imaging and screening technologies.
vivoVerse Announces Intent to Grant Utility Patent on the vivoChip by the European Patent Office
vivoVerse (formerly operating as Newormics), a developer of the first high-throughput, high-content screening platforms for use with in vivo small animal models, announced that the European Patent Office (EPO) intends to grant a patent covering the vivoChip® technology, the device design and use for C. elegans studies.
More news...
